We are live on ! Find out more
RG

Redmile Group Portfolio holdings

AUM $1.49B
1-Year Est. Return 208.7%
This Fund
S&P 500
This Quarter Est. Return
+39.83%
1 Year Est. Return
+208.7%
3 Year Est. Return
+777.5%
5 Year Est. Return
+1,114.43%
10 Year Est. Return
+23,630.52%
AUM
$1.49B
AUM Growth
-$20.6M
Cap. Flow
-$290M
Cap. Flow %
-19.48%
Top 10 Hldgs %
73.48%
Holding
39
New
4
Increased
5
Reduced
23
Closed
–

Top Buys

Rank Stock Value
1
AGMB
AgomAb Therapeutics NV
AGMB
+$29M
2
CLYM
Climb Bio
CLYM
+$12.7M
3
AURA icon
Aura Biosciences
AURA
+$11.9M
4
STTK icon
Shattuck Labs
STTK
+$8.43M
5
ODTX
Odyssey Therapeutics
ODTX
+$7.45M

Top Sells

Rank Stock Value
1
SRRK icon
Scholar Rock
SRRK
+$230M
2
NRIX icon
Nurix Therapeutics
NRIX
+$62.3M
3
ANNX icon
Annexon
ANNX
+$14.8M
4
IMNM icon
Immunome
IMNM
+$13.9M
5
KRYS icon
Krystal Biotech
KRYS
+$12.4M

Sector Composition

Rank Sector Weight
1 Healthcare 100%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
SRRK icon
1
Scholar Rock
SRRK
$7.04B
$237M 15.92%
4,311,092
-4,755,529
-52% -$230M
KRYS icon
2
Krystal Biotech
KRYS
$10.4B
$235M 15.77%
632,005
-41,500
-6% -$12.4M
STOK icon
3
Stoke Therapeutics
STOK
$2.04B
$129M 8.67%
3,945,920
-218,200
-5% -$7M
IMNM icon
4
Immunome
IMNM
$3.13B
$104M 6.99%
4,911,590
-647,295
-12% -$13.9M
NRIX icon
5
Nurix Therapeutics
NRIX
$2.72B
$98.8M 6.64%
4,073,787
-3,659,021
-47% -$62.3M
ABSI icon
6
Absci
ABSI
$1.49B
$78.1M 5.24%
6,739,675
-1,513,641
-18% -$8.53M
ANNX icon
7
Annexon
ANNX
$942M
$67.8M 4.55%
11,869,877
-2,679,891
-18% -$14.8M
RGNX icon
8
Regenxbio
RGNX
$638M
$52.3M 3.51%
4,368,804
– –
STTK icon
9
Shattuck Labs
STTK
$707M
$47.8M 3.21%
6,892,033
+1,352,309
+24% +$8.43M
NGNE icon
10
Neurogene
NGNE
$732M
$44.4M 2.98%
1,412,199
-47,400
-3% -$1.3M
BEAM icon
11
Beam Therapeutics
BEAM
$3.03B
$40M 2.68%
1,164,259
-73,400
-6% -$2.22M
AGMB
12
AgomAb Therapeutics NV
AGMB
$649M
$35.5M 2.38%
2,733,926
+2,577,676
+1,650% +$29M
FATE icon
13
Fate Therapeutics
FATE
$291M
$34.8M 2.33%
12,872,946
– –
IDYA icon
14
IDEAYA Biosciences
IDYA
$3.87B
$23.9M 1.6%
640,202
+119,085
+23% +$3.65M
SLN
15
Silence Therapeutics
SLN
$834M
$23.8M 1.6%
2,164,777
– –
COGT icon
16
Cogent Biosciences
COGT
$6.02B
$19.5M 1.31%
503,321
-184,715
-27% -$6.46M
SLDB icon
17
Solid Biosciences
SLDB
$1.05B
$19.5M 1.31%
1,948,695
-63,200
-3% -$479K
NUVB icon
18
Nuvation Bio
NUVB
$2.34B
$17.2M 1.16%
3,031,009
-122,247
-4% -$597K
CLDX icon
19
Celldex Therapeutics
CLDX
$3.07B
$16.1M 1.08%
433,921
+172,413
+66% +$5.57M
CLYM
20
Climb Bio
CLYM
$837M
$16M 1.07%
+1,226,330
New +$12.7M
ALXO icon
21
ALX Oncology
ALXO
$277M
$15.3M 1.03%
7,392,504
-571,684
-7% -$1.02M
BMRN icon
22
BioMarin Pharmaceuticals
BMRN
$12.5B
$15.2M 1.02%
265,169
+91,310
+53% +$5M
XENE icon
23
Xenon Pharmaceuticals
XENE
$5.81B
$13.8M 0.93%
229,374
-33,300
-13% -$1.85M
ZYME icon
24
Zymeworks
ZYME
$2.02B
$12.9M 0.86%
491,654
– –
ADCT icon
25
ADC Therapeutics
ADCT
$146M
$12.3M 0.83%
11,526,710
-3,943,792
-25% -$11.5M
1
2

Similar funds

FCM
Fairholme Capital Management South Miami, Florida $1.49B AUM 28.35% 1-Year Est. Return
MM
Main Management San Francisco, California $1.49B AUM 22.28% 1-Year Est. Return
WA
WBH Advisory Baltimore, Maryland $1.49B AUM 20.41% 1-Year Est. Return
ACB
Aristotle Capital Boston Boston, Massachusetts $1.49B AUM 32.81% 1-Year Est. Return
LCS
Levin Capital Strategies New York $1.49B AUM 30.44% 1-Year Est. Return
GAM
Gemmer Asset Management Walnut Creek, California $1.49B AUM 42.66% 1-Year Est. Return
MFWP
Mosaic Family Wealth Partners St. Louis, Missouri $1.49B AUM 26.43% 1-Year Est. Return
PMG
ProVise Management Group Clearwater, Florida $1.49B AUM 21.79% 1-Year Est. Return

Redmile Group's Q2 2026 Portfolio in Review

As of Q2 2026, Redmile Group held 39 positions worth $1.49B, down 1.4% from $1.51B the previous quarter. Its ten largest holdings account for 73% of the portfolio.

Redmile Group withdrew a net $290M in Q2 2026, reducing 23 holdings. Its largest reduction was Scholar Rock, cutting an estimated $230M.

By sector, the portfolio is most concentrated in Healthcare at 100% of assets, unchanged from a quarter earlier.

Against the trend, Redmile Group opened a new position in Climb Bio worth $16M.

  • Redmile Group's largest Q2 2026 buy was Climb Bio: 1,226,330 shares worth $16M.
  • Redmile Group added most to AgomAb Therapeutics NV in Q2 2026, an estimated $29M increase.
  • Redmile Group's biggest Q2 2026 reduction was Scholar Rock, cutting an estimated $230M.
  • Redmile Group's ten largest holdings make up 73% of its $1.49B portfolio in Q2 2026.
  • Redmile Group opened 4 new positions and closed 0 in Q2 2026.
  • Redmile Group's portfolio value fell 1.4% quarter-over-quarter to $1.49B.

Based on Redmile Group's 13F filing for Q2 2026, filed 14 Aug 2026.